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Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin
lymphomas with poor prognosis. Their molecular pathogenesis has not been
entirely elucidated. We previously showed that 6q24 is one of the most fre-
quently deleted regions in primary thyroid T-cell lymphoma. In this study, we
extended the analysis to other subtypes of PTCL and performed functional assays
to identify the causative genes of PTCL that are located on 6q24. Genomic loss of
6q24 was observed in 14 of 232 (6%) PTCL cases. The genomic loss regions identi-
fied at 6q24 always involved only two known genes, STX11 and UTRN. The
expression of STX11, but not UTRN, was substantially lower in PTCL than in nor-
mal T-cells. STX11 sequence analysis revealed mutations in two cases (one clinical
sample and one T-cell line). We further analyzed the function of STX11 in 14 cell
lines belonging to different lineages. STX11 expression only suppressed the pro-
liferation of T-cell lines bearing genomic alterations at the STX11 locus. Interest-
ingly, expression of a novel STX11 mutant (p.Arg78Cys) did not exert suppressive
effects on the induced cell lines, suggesting that this mutant is a loss-of-function
mutation. In addition, STX11-altered PTCL not otherwise specified cases were
characterized by the presence of hemophagocytic syndrome (67% vs 8%,
P = 0.04). They also tended to have a poor prognosis compared with those with-
out STX11 alteration. These results suggest that STX11 plays an important role in
the pathogenesis of PTCL and they may contribute to the future development of
new drugs for the treatment of PTCL.
P eripheral T-cell lymphomas (PTCL) are tumors derivedfrom mature T-cells. They are relatively rare and account
for approximately 10% of non-Hodgkin Lymphomas.(1) A
recent epidemiological study demonstrated that the incidence
of PTCL is increasing in Japan and the USA.(2) PTCL are
known to be clinically, histopathologically and genetically
heterogeneous.(3,4) Recently, studies employing unbiased and
genome-wide methods showed that the genetic alterations were
involved in the pathophysiology of PTCL.(5–16) Because of the
heterogeneity of the diseases, additional genomic alterations
are predicted to contribute to the pathophysiology of PTCL.
Therefore, the molecular pathogenesis of PTCL has not been
fully elucidated.
We previously analyzed the genomic alterations associated
with primary T-cell lymphoma of the thyroid (primary thyroid
T-cell lymphoma [PTTL]).(17) In that study, we observed that
67% of PTTL cases showed genomic loss at 6q24.2. The mini-
mal common region (MCR) lost in those cases contained
STX11 and ⁄or UTRN, suggesting the involvement of these
genes in the pathophysiology of PTTL. STX11 is a member of
the t-SNAP receptor (t-SNARE) family. A biallelic germline
mutation in STX11 is known to cause familial hemophagocytic
lymphohistiocytosis type 4 (FHL type 4).(18) Although
degranulation of cytotoxic T-cells (CTL) and natural killer
(NK) cells is impaired by STX11 deficiency, the precise molec-
ular function of STX11 is largely unknown.(19–21) The inci-
dence of T-cell lymphomas in patients with FHL type 4 has
not been reported.(18,22,23) Moreover, Stx11 knockout mice are
normal in development and differentiation of T-cells.(19,21)
UTRN encodes utrophin, a component of cytoskeleton.
Because nonsense and frameshift mutations in UTRN have
been reported in a small number of cancers, UTRN is regarded
as a tumor suppressor gene.(24) However, alterations of UTRN
have not been described in malignant lymphomas such as
PTCL.
In this study, we demonstrated for the first time that STX11
functions as an important tumor suppressor gene in PTCL by
using gene expression and functional analyses. In addition, we
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identified a loss-of-function mutation of STX11 that is associ-
ated with T-cell lymphoma.
Materials and Methods
Samples and cell lines. The Institute Review Board of the
Aichi Cancer Center approved all the samples and medical
records used in our study. Most patients with PTCL-NOS and
PTTL were treated with anthracycline-based chemotherapy, as
previously reported.(6,17) Clinicopathological findings were
reexamined from the results of previous our studies.(6,25) CD4-
positive cells were used as controls in this study and were
purified as previously reported.(26)
Six T-cell neoplasm cell lines (ST1, KOB, Su9T01, KOB,
Hut102, Hut78 and Jurkat) were used in this study. In addition
to the six T-cell lines, an NK cell line (NKL), four B-cell lines
(Reh, SUDHL6, Raji and Jeko1), a myeloid cell line (K562)
and three epithelial cell lines (293T, MCF7 and HeLa) were
also analyzed. Cell lines were cultured as previously
reported.(27,28) The cell lines used in the present study are sum-
marized in Supplementary Table S1.
Array comparative genomic hybridization analysis. Focusing
on chromosome 6q loss, we reexamined our previous compara-
tive genomic hybridization (CGH) data on 430 cases of non-
Hodgkin’s lymphoma. These data comprised six PTTL,(17) 51
PTCL-NOS,(6) 62 adult T-cell leukemia ⁄ lymphoma (ATL; 35
and 27 cases of the acute- and chronic-type cases, respec-
tively),(16) 35 NK-cell lymphoma,(27) 118 diffuse large B-cell
lymphoma (DLBCL),(29,30) 80 follicular lymphoma,(31) 26 Bur-
kitt lymphoma(32) 21 mantle cell lymphoma(33) and 31
mucosa-associated lymphoid tissue lymphoma(34) cases. In
addition, we evaluated the genomic loss of 6q using previous
results of the genomic alterations in 39 angioimmunoblastic T-
cell lymphoma (AITL)(35) and 74 anaplastic large cell lym-
phoma (ALCL) cases.(36) Platforms of array CGH used in
these analyses and the accession numbers for the database are
described in Supplementary Table S2.
Gene expression analysis. We evaluated the expression levels
of STX11 and UTRN using published data (GSE6338 and
GSE19069).(5,37) Using quantitative real-time RT-PCR, we
measured the gene expression levels of STX11 in 29 cases of
PTCL-NOS, four cases of PTTL, and six T-cell lines, for
which adequate RNA was available.
Mutation analysis of STX11. The coding region of STX11
was amplified from genomic DNA and cDNA by using PCR.
The PCR primers used are detailed in a previous study.(18)
Western blot analysis. Western blot analyses were performed
using a rabbit polyclonal antibody specific to STX11 (1:1000,
HPA007992; Sigma-Aldrich, St. Louis, MO, USA), a mouse
monoclonal antibody specific to Actin (1:1000, AC-40; Sigma-
Aldrich) and a mouse monoclonal antibody specific to FLAG
M2 (1:1000; Sigma-Aldrich).
Gene transduction, and cell proliferation, apoptosis and cell-cy-
cle assays. We used the Retro-X Tet-Off Advanced Inducible
Expression System (Clontech, Palo Alto, CA, USA).
Table 1. Frequency of STX11 loss in non-Hodgkin’s lymphoma
Histological subgroup n (%)
PTTL 4 ⁄ 6 (67)
PTCL-NOS 4 ⁄ 51 (8)
ATL 3 ⁄ 62 (5)
Acute type 3 ⁄ 35 (9)
Chronic type 0 ⁄ 27 (0)
AITL† 0 ⁄ 39 (0)
ALCL‡ 3 ⁄ 74 (3)
PTCL 14 ⁄ 232 (6)
NK-cell lymphoma 7 ⁄ 35 (20)
DLBCL 28 ⁄ 118 (24)
Mantle cell lymphoma 3 ⁄ 21 (14)
Follicular lymphoma 8 ⁄ 80 (10)
Burkitt lymphoma 2 ⁄ 26 (8)
MALT lymphoma 1 ⁄ 31 (3)
Total 63 ⁄ 543 (12)
†This was determined using the published result reported by Thorns
et al.(35) ‡This was determined using the published result reported by
Salaverria et al.(36) AITL, angioimmunoblastic lymphoma; ALCL,
anaplastic large cell lymphoma; ATL, adult T-cell leukemia ⁄ lymphoma;
DLBCL, diffuse large B-cell lymphoma; MALT lymphoma, mucosa-asso-
ciated lymphoid tissue lymphoma; PTCL, peripheral T-cell lymohomas;
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; PTTL,
primary thyroid T-cell lymphoma.
Fig. 1. Status of STX11 in primary thyroid T-cell lymphoma (PTTL) and peripheral T-cell lymphomas (PTCL)-NOS genomes. (a) The horizontal
axis indicates the frequency of chromosome 6 alterations in PTTL cases (left). Red and blue areas represent genomic gains and losses, respec-
tively. Heat map analyses showing log2 ratios of PTTL (middle) and PTCL-NOS (right) tumor cells relative to normal controls. White, blue and
red represent genomic diploids, losses and gains, respectively. Arrowheads indicate the STX11 ⁄ UTRN locus. Data of PTTL were modified from
our previous study.(17) (b) The expression levels of STX11 and UTRN, genes contained within the minimal common region (MCR), were deter-
mined using published data (GSE6338 and GSE19069). The data included PTCL-NOS (n = 78), angioimmunoblastic T-cell lymphoma (AITL;
n = 43), anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL, n = 16), ALK-positive ALCL (n = 20) and adult T-cell
leukemia ⁄ lymphoma cases (ATL; n = 13), as well as CD4-positive T-cells (n = 5), CD8-positive T-cells (n = 5), HLA-DR-positive T-cells (n = 5) and
HLA-DR-negative T-cells (n = 5). Significant differences were observed in each pair (*P < 0.05, one way-analysis of variance, Tukey’s correla-
tion). (c) STX11 expression levels in PTCL were normalized to b-actin and compared to that of healthy donor CD4-positive cells. Relative
expression is shown. (Left) STX11 expression in T-cell lines was lower than in normal CD4-positive T-cells. Genomic loss of STX11 is indicated
(*). (Right) Four PTCL-NOS and PTTL cases carrying genomic alterations of STX11 and 29 cases without STX11 alterations were analyzed. (d)
DNA sequencing chromatogram of a T-cell line (ST1) showing a missense mutation in STX11 (p. Arg78Cys, c.232C>T; upper panel). A represen-
tative sample that did not carry the mutation is shown in the middle panel. The lower panel shows a schematic representation of the STX11
protein, depicting the location of the syntaxin N-terminus (SynN) and SNAP receptor (SNARE) domains. The arrowhead indicates the position
of the mutation. (e) Western blot analysis of STX11 and b-Actin in normal CD4-positive and CD4-negative cells, and six T-cell lines. To detect
STX11, we introduced Flag-STX11 into Jurkat and Su9T01 cells using the Tet-OFF system. Western blots of induced STX11 probed with anti-
STX11 antibody are shown in the four lanes to the right. In this system, STX11 is expressed in response to doxycycline (DOX) removal (see also
Suppl. Fig. S1c). The arrowheads mark STX11 protein signals. The middle panel shows a longer exposure of the same membrane. Signals were
converted to a numerical value by using the ImageJ software. The ratio of STX11 to actin expression was calculated and displayed below each
lane. The STX11 ⁄ actin ratio in Jurkat cells is used as a control. Heterozygous genomic loss and heterozygous missense mutation of STX11 are
indicated by * and **, respectively. (f) Genomic loss of the STX11 region was observed in 67% of PTTL cases (n = 6), whereas 10% of PTCL-
NOS cases (n = 51) showed genomic losses and mutations of STX11 (P < 0.01, Fisher’s exact test). Synonymous mutations were excluded from
the analysis.
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Cell proliferation, apoptosis and cell-cycle assays were per-
formed on the stable Tet-OFF cell lines generated for each
gene. To induce the target gene, doxycycline (DOX) was
removed using three washes (day 0), according to the manu-
facturer’s protocol. All of these experiments were performed
in triplicate. Detailed methods are described in previous stud-
ies.(27)
Statistical analyses. All the statistical analyses were per-
formed using EZR (Saitama Medical Center, Jichi Medical
University), a modified version of R commander software.(38)
Detailed methods can be found in Supplementary Data S1.
Results
Recurrent genomic loss of 6q24.2 found in subtypes of non-
Hodgkin’s lymphoma. We investigated the genomic loss
frequency of 6q24 in various subtypes of non-Hodgkin lym-
phoma. Heterozygous loss of 6q24 was observed in 6%
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(n = 232) of PTCL cases (Table 1), whereas homozygous
loss of this region was not observed in our analysis. The
loss of 6q24 occurred most frequently in the TTCL cases
(67%, n = 6). This genomic deficiency was also frequently
observed in DLBCL and NK-cell lymphomas (24% and
20%, respectively), and the genes located near the 6q24
region are implicated in the pathophysiology of these lym-
phoma subtypes. TNFAIP3 and PRDM1 are implicated in
DLBCL,(39–41) and FOXO3 and PRDM1 are thought to be
involved in NK-cell lymphoma.(27,42) However, the genes
involved in the pathophysiology of PTCL, such as PTCL-
NOS, have not been identified in 6q24 locus. Therefore, we
focused on identifying the genes located in 6q24 that are
responsible for PTCL.
The genes that are contained within the MCR are most
likely the candidate genes in the altered regions. Among the
6q24 losses observed in analyzed PTCL cases, the narrowest
one was observed in a case of PTTL (Fig. 1a).(17) The
MCR contained only two known coding genes, STX11 and
UTRN. Case 39 of PTCL-NOS showed approximately 4.8-
Mb loss at 6q24.1–6q24.3, which was the second narrowest
loss in our analysis (Fig. 1a and Suppl. Table S3). This loss
involved 12 known genes, including STX11 and UTRN, but
not TNFAIP3, FOXO3 and PRDM1 (Fig. 1a). Thus, we
regarded STX11 and UTRN as candidate genes contained
within the 6q24 region that are predicted to be involved in
pathogenesis of PTCL. Genomic losses of 6q24 that
included STX11 and UTRN were observed in 8% (n = 51)
of PTCL-NOS cases and a T-cell line (Su9T01) (Table 1
and Suppl. Fig. S1a).
Selection of the candidate gene located in minimal common
region of 6q24.2. Differences in STX11 and UTRN expression
levels in PTCL compared to normal T-cells were analyzed
using previously published gene expression profiling data
(Fig. 1b). Notably, STX11 expression was significantly lower
in PTCL than in the normal T-cells, but UTRN expression did
not change. These data are consistent with that of our previous
study reporting the reduction of STX11, but not UTRN expres-
sion, in PTTL cases missing 6q24.2.(17)
To accurately assess STX11 expression in PTCL-NOS and
PTTL cases and T-cell lines, we performed quantitative RT-
PCR. STX11 expression was lower in T-cell lymphomas and
in all cases with 6q24 loss than in the normal T-cells (Fig. 1c
and Suppl. Table S4). The genes whose expression was
affected by copy number changes were considered candidate
genes in the regions of genomic alteration. Therefore, we
regarded STX11 as the most likely candidate gene located in
6q24.
Mutation and protein blot analyses of STX11. Mutation analy-
sis was performed for PTCL-NOS and PTTL cases, and for
T-cell lines to further evaluate the genomic alteration of
STX11. This sequence analysis revealed a missense mutation
in one T-cell line (ST1); the arginine at position 78 was
changed to cysteine (p.Arg78Cys, c.232C>T; Fig. 1d). In
addition, a PTCL-NOS case (Case 9) had a one-nucleotide
substitution in the region before ATG (c.-19C>G;
Suppl. Fig. S1b). Synonymous mutations were observed in a
T-cell line (Jurkat, c.462C>T) and a PTCL-NOS case (Case
48, c.570C>T). The latter mutation was registered as a
single-nucleotide polymorphism in the National Center
for Biotechnology Information database (http://
www.ncbi.nlm.nih.gov/snp/, rs148354227).
Western blots performed using anti-STX11 antibodies indi-
cated that STX11 expression was significantly lower in T-cell
lines than in the normal CD4-positive and CD4-negative cells
(Fig. 1e and Suppl. Fig. S1c). Longer exposure of the mem-
branes allowed us to evaluate STX11 expression in the T-cell
lines. In Su9T01 cells that have a genomic loss of STX11,
STX11 expression was reduced, unlike that in the other T-cell
lines that have not lost STX11.
In total, 17% (11 ⁄63; 51 PTCL-NOS cases, six PTTL cases,
and six T-cell lines) of the analyzed cases had genomic loss
and mutation of STX11. Notably, genomic alterations of STX11
were significantly more prevalent in PTTL (4 ⁄6; 67%) than in
PTCL-NOS (5 ⁄51; 10%) (P < 0.01; Fig. 1f). No apparent cor-
relations were observed between the distribution of STX11
alterations and the alterations that were frequently observed in
PTCL-NOS cases (Suppl. Fig. S1d). A RHOA mutation
(p.Gly17Val) is reportedly observed in PTCL.(12–14) Using
Sanger sequencing, we analyzed this mutation in the cases
with STX11 alterations, and no mutations were observed (data
not shown).
Functional analyses of STX11. We speculated that STX11
plays a key role as a tumor suppressor gene in PTCL
because genetic alteration of STX11 and its reduced expres-
sion were detected in PTCL samples. Therefore, we
introduced STX11 into T-cell lines by using an established
Tet-OFF system to investigate its function.(27) Because PTTL
and PTCL-NOS cell lines were not available, we used
ATL and T-cell lineage acute lymphoblastic leukemia cell
lines.
In T-cell lines with genomic alterations of STX11 (Su9T01
and ST1), induction of STX11 suppressed proliferation
(Fig. 2a). Induced STX11 expression had no effect on Jurkat
cells that did not carry an alteration of STX11. Although
proliferation of Su9T01 and ST1 cell lines was suppressed
by the expression of STX11 under standard serum conditions
(10% FCS), this suppression was more apparent under low-
serum conditions (1% FCS; Fig. 2b). As shown in Figure 2c,
STX11 was successfully induced in each cell line by the
removal of DOX. To further characterize the suppressive
effect of STX11, we performed apoptosis and cell cycle
assays in Su9T01 cells (Fig. 2d,e). Expression of STX11
induced cellular apoptosis in the cell line (Figs. 2d and
Suppl. Fig. S2a), although the number of apoptotic cells
induced by STX11 was relatively small.
The STX11 Arg78Cys mutant allele we identified in a T-cell
line (ST1) by using capillary sequencing (Fig. 1d and
Suppl. Fig. S2b) was also transduced into the ST1 and Su9T01
cells. Induction of STX11 Arg78Cys did not have a suppres-
sive effect on these cell lines (Fig. 2f and Suppl. S2c). These
results indicate that STX11 Arg78Cys is a loss-of-function
mutation.
Suppressive effect of STX11 induction only in T-cell lines. To
determine whether the suppressive effect is specific to PTCL
with STX11 alteration, we next introduced STX11 and GFP
into cell lines of various lineages by using a Tet-Off sys-
tem and performed cell proliferation assays. Forced
STX11 expression suppressed the proliferation of ST1 and
Su9T01 cells, but did not affect the other cell lines ana-
lyzed in this study (Fig. 3a and Suppl. Fig. S3). Although
Jeko1 and NKL also had genomic losses of STX11, induc-
tion of STX11 did not have a suppressive effect on these
cell lines.
Clinicopathological findings of STX11 alteration. Previously,
we showed that PTTL is a distinct entity from PTCL-
NOS.(17) Therefore, we separately analyzed the clinicopatho-
logical characteristics of STX11 alteration in the PTTL and
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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PTCL-NOS cases (Tables 2 and 3 and Suppl. Tables S5 and
S6). Among PTCL-NOS cases, patients with STX11 alter-
ation tended to have poorer prognoses than those without
the alteration (P = 0.07). In addition, STX11-altered PTCL-
NOS cases were characterized by the presence of
hemophagocytic syndrome at diagnosis (67% vs 8%,
P = 0.04). STX11 alteration was frequently observed in
PTTL characterized by past histories of autoimmune diseases
and extra-nodal lesions.(17) However, no significant differ-
ences in these findings were observed among PTCL-NOS
cases based on STX11 alteration. Morphologically, STX11-al-
tered PTCL-NOS cases were associated with anaplastic
nuclei compared with the STX11-wild type cases (60% vs
9%, P = 0.016), although the numbers of the analyzed cases
were small. No significant differences were seen in other
immunohistochemical findings. In PTTL cases, there were
no differences in clinicopathological findings based on
STX11 alteration.
Discussion
Genomic alterations of STX11 in T-cell lymphomas. In the pre-
sent study, we examined the MCR of 6q24 loss and showed
that STX11 plays an important role in PTCL. Genomic alter-
ation of STX11 in malignancies had not been previously
reported. Therefore, our study is the first to investigate STX11
in this context. The loss of 6q occurred frequently in DLBCL
and NK-cell lymphomas, but our functional analysis indicated
that STX11 does not act as a tumor suppressor gene in these
types of lymphomas (Fig. 3).
Interestingly, overexpression of STX11 had suppressive
effects on T-cell lines, but only on those with STX11
Fig. 2. Functional characteristics of STX11 in T-cell lymphomas. (a) The effect of reestablishing STX11 expression in Su9T01 (STX11-deficient),
ST1 (STX11 mutant) and Jurkat cells (wild-type STX11). The horizontal axis indicates the time elapsed after doxycycline (DOX) removal. The verti-
cal axis indicates the average cell numbers with standard deviation. Cell numbers were counted using the trypan blue exclusion assay on days 2,
4 and 6 post-DOX removal. Experiments were performed in triplicate. The upper and lower panels show the result of reestablishing STX11
expression and GFP expression, respectively. (b) Cell proliferation analysis of ST1 and Su9T01 cells under low-serum conditions (1% FCS). (c) Using
anti-FLAG and anti-b-actin antibodies, the induction efficiency of Flag-STX11 was evaluated in the cells. Signals were converted to a numerical
value by using the ImageJ software. The expression ratio relative to actin was calculated and is shown below each lane. (d) Annexin V-positive
STX11-induced Su9T01 cells were quantified using flow cytometry on days 2 and 5, following the removal of DOX. Experiments were performed
in triplicate, and averages with standard deviations are shown. Significant differences were observed between DOX () and DOX (+) samples
(*P < 0.01, t-test). (e) Cell cycle assays were conducted by staining cells with propidium iodide (PI) on days 2 and 5. Induction of STX11 did not
alter the cell cycle of Su9T01 cells. (f) Arg78Cys mutant STX11 (mSTX11) was introduced into Su9T01 and ST1 cells. The ratio of proliferating cells
in the absence versus presence of DOX (DOX [] ⁄ DOX [+]) on day 6 is shown on the vertical axis. Experiments were performed in triplicate. Stan-
dard deviations and average values are shown. Significant differences were observed in each pair (*P < 0.05, one-way analysis of variance with
Bonferroni adjustment). ns, no significance.
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alteration. These results indicate that the genetic events of
STX11 are involved in the pathophysiology of PTCL. STX11
mRNA and protein levels were reduced in PTCL with or with-
out STX11 alterations compared with normal cells. These
results suggested that epigenetic events modify the expression
of STX11. Because of the limited availability of samples, we
could not perform epigenetic analyses for STX11. However,
this should be addressed in future studies.
Haploinsufficiency of STX11 in T-cell lymphoma. Syntaxin 11,
encoded by STX11, is a t-SNARE protein that plays a role in
binding vesicles to cell membranes.(43) Homozygous loss and
mutation of STX11 in the germline causes FHL type 4.(18) The
genomic alterations of STX11 in PTCL were all heterozygous,
suggesting that PTCL is associated with STX11 haploinsuffi-
ciency. The loss-of-function STX11 mutation (p.Arg78Cys,
c.232C>T) identified in this study was not observed in FHL
type 4 patients. Therefore, the role of STX11 alteration in
PTCL might differ from that in FHL type 4. We speculate that
the STX11 Arg78Cys mutant will provide further insight into
the pathobiology of STX11 in PTCL and will reveal novel
roles of STX11 in normal T-cells.
Contribution of STX11 alteration to peripheral T-cell lymphoma
pathophysiology. Until now, T-cell lymphoma has not been
found to occur in Stx11 knockout mice or in patients with
FHL type 4. Therefore, we surmised that STX11 alteration
alone does not cause lymphoma. In fact, we found that the
cases with STX11 alterations also had genomic alterations
that were typically found in PTCL-NOS samples (Suppl.
Fig. S1d).
We also found that PTCL-NOS cases with STX11 alterations
tended to have poor prognoses, show a hemophagocytosis, and
possess anaplastic nuclei (Tables 2 and 3). A previous study
reported that expression of cytotoxic molecules tended to be
associated with hemophagocytosis in PTCL-NOS,(44) but
STX11-altered PTCL-NOS with hemophagocytosis lacked an
expression of cytotoxic molecules. It is speculated that addi-
tional genomic alteration(s) are required for the pathophysiol-
ogy of PTCL having STX11 alteration. To reveal such genes
that act synergistically with STX11, future studies using the
appropriate T-cell lymphoma model mice are needed.(45)
In conclusion, we identified that STX11 loss occurred in a
portion of PTCL cases. STX11 mutations, including a loss-of
function mutation, were also observed in PTCL. Overexpres-
sion of STX11 only suppressed proliferation of T-cell lines
with STX11 alterations, indicating that STX11 acts as a T-cell
lineage-specific tumor suppressor gene. We believe that these


















Case 9 4 F IVS + + (Liver) 0 0 + 15 Death
Case 31 3 M NA NA NA NA NA NA 3 Death
Case 39 48 M NA NA NA NA NA NA 11 Death
Case 42 80 F IV + + (Soft tissue) 0 0 + 29 Survival
Case 46 56 M III +  0 0 0 1 Death
†Representations in previous Nakagawa et al. paper were used.(6) CS, clinical stage; F, female; LDH, lactate dehydrogenase; M, male; NA, not
available; OS, overall survival; ULN, upper limit of normal.
Fig. 3. Reestablished STX11 expression in cells of various lineages.
STX11 or GFP was transduced into 14 cell lines using the Tet-OFF sys-
tem. The average number of proliferating cells expressed as a ratio
(DOX [] ⁄ DOX [+]) on day 6; the standard deviation is shown. Experi-
ments were performed in triplicate. Significant differences were
observed in each pair (*P < 0.05, t-test). Genomic loss and mutation of
STX11 are indicated by ** and ***, respectively.











CD3 CD4 CD8 TIA-1 CCR4* CCR3* CXCR3* EBER
Ki-67
(%)
Case 9 Anaplastic    + +    +  + 20
Case 31 Large    NA NA NA NA NA NA NA NA NA
Case 39 Anaplastic    NA NA NA NA NA NA NA NA NA
Case 42 Pleomorphic    + +   +    30
Case 46 Anaplastic    + +     +  80
“” means negative, and “+” means positive. NA, not available. *Representations in previous Nakagawa et al.(6) paper were used.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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findings provide a novel approach to understand the molecular
mechanisms involved in PTCL pathogenesis.
Acknowledgments
This work was supported in part by Grants-in-Aid from the Ministry of
Health, Labor, and Welfare of Japan; the Ministry of Education, Cul-
ture, Sports, Science, and Technology of Japan; the Japan Society for
the Promotion of Science; and the Takeda Science Foundation. The
authors thank Drs Tohru Izumi, Daisuke Niino, Kotaro Arita and Tat-
suo Kakiuchi for their discussions and encouragement throughout this
study. We also thank Yumiko Kasugai, Seiko Sato and Kyoko Hirano
for their technical assistance.
Disclosure Statement
The authors have no conflict of interest to declare.
References
1 Piccaluga PP, Tabanelli V, Pileri SA. Molecular genetics of peripheral T-cell
lymphomas. Int J Hematol 2014; 99: 219–26.
2 Chihara D, Ito H, Matsuda T et al. Differences in incidence and trends of
haematological malignancies in Japan and the United States. Br J Haematol
2014; 164: 536–45.
3 Swerdlow SH, Campo E, Harris NL et al., ed. WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. Lyon, France:
International Agency for Research on Cancer; 2008.
4 Pileri SA, Piccaluga PP. New molecular insights into peripheral T cell lym-
phomas. J Clin Invest 2012; 122: 3448–55.
5 Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of
peripheral T cell lymphoma, unspecified, reveals distinct profiles and new
potential therapeutic targets. J Clin Invest 2007; 117: 823–34.
6 Nakagawa M, Nakagawa-Oshiro A, Karnan S et al. Array comparative geno-
mic hybridization analysis of PTCL-U reveals a distinct subgroup with
genetic alterations similar to lymphoma-type adult T-cell leukemia ⁄ lym-
phoma. Clin Cancer Res 2009; 15: 30–8.
7 Braun FC, Grabarczyk P, Mobs M et al. Tumor suppressor TNFAIP3 (A20)
is frequently deleted in Sezary syndrome. Leukemia 2011; 25: 1494–501.
8 Koskela HL, Eldfors S, Ellonen P et al. Somatic STAT3 mutations in large
granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–13.
9 Boi M, Rinaldi A, Kwee I et al. PRDM1 ⁄ BLIMP1 is commonly inactivated
in anaplastic large T-cell lymphoma. Blood 2013; 122: 2683–93.
10 Odejide O, Weigert O, Lane AA et al. A targeted mutational landscape of
angioimmunoblastic T cell lymphoma. Blood 2014; 123: 1293–6.
11 Odqvist L, Sanchez-Beato M, Montes-Moreno S et al. NIK controls classical
and alternative NF-kappaB activation and is necessary for the survival of
human T-cell lymphoma cells. Clin Cancer Res 2013; 19: 2319–30.
12 Palomero T, Couronne L, Khiabanian H et al. Recurrent mutations in epige-
netic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Nat Genet 2014; 46: 166–70.
13 Sakata-Yanagimoto M, Enami T, Yoshida K et al. Somatic RHOA mutation
in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 171–5.
14 Yoo HY, Sung MK, Lee SH et al. A recurrent inactivating mutation in
RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014;
46: 371–5.
15 Vaque JP, Gomez-Lopez G, Monsalvez V et al. PLCG1 mutations in cuta-
neous T-cell lymphomas. Blood 2014; 123: 2034–43.
16 Yoshida N, Karube K, Utsunomiya A et al. Molecular characterization of
chronic-type adult T-cell leukemia ⁄ lymphoma. Cancer Res 2014; 74: 6129–38.
17 Yoshida N, Nishikori M, Izumi T et al. Primary peripheral T-cell lymphoma,
not otherwise specified of the thyroid with autoimmune thyroiditis. Br J
Haematol 2013; 161: 214–23.
18 zur Stadt U, Schmidt S, Kasper B et al. Linkage of familial hemophagocytic
lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of
mutations in syntaxin 11. Hum Mol Genet 2005; 14: 827–34.
19 Sepulveda FE, Debeurme F, Menasche G et al. Distinct severity of HLH in
both human and murine mutants with complete loss of cytotoxic effector
PRF1, RAB27A, and STX11. Blood 2013; 121: 595–603.
20 Bryceson YT, Rudd E, Zheng C et al. Defective cytotoxic lymphocyte
degranulation in syntaxin-11 deficient familial hemophagocytic lymphohisti-
ocytosis 4 (FHL4) patients. Blood 2007; 110: 1906–15.
21 Kogl T, Muller J, Jessen B et al. Hemophagocytic lymphohistiocytosis in
syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood
2013; 121: 604–13.
22 Yamamoto K, Ishii E, Horiuchi H et al. Mutations of syntaxin 11 and
SNAP23 genes as causes of familial hemophagocytic lymphohistiocytosis
were not found in Japanese people. J Hum Genet 2005; 50: 600–3.
23 Rudd E, Goransdotter Ericson K, Zheng C et al. Spectrum and clinical
implications of syntaxin 11 gene mutations in familial haemophagocytic
lymphohistiocytosis: association with disease-free remissions and
haematopoietic malignancies. J Med Genet 2006; 43: e14.
24 Li Y, Huang J, Zhao YL et al. UTRN on chromosome 6q24 is mutated in
multiple tumors. Oncogene 2007; 26: 6220–8.
25 Vose J, Armitage J, Weisenburger D, International TCLP. International
peripheral T-cell and natural killer ⁄ T-cell lymphoma study: pathology find-
ings and clinical outcomes. J Clin Oncol 2008; 26: 4124–30.
26 Umino A, Nakagawa M, Utsunomiya A et al. Clonal evolution of adult T-
cell leukemia ⁄ lymphoma takes place in the lymph nodes. Blood 2011; 117:
5473–8.
27 Karube K, Nakagawa M, Tsuzuki S et al. Identification of FOXO3 and
PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by geno-
mic and functional analyses. Blood 2011; 118: 3195–204.
28 Karube K, Tsuzuki S, Yoshida N et al. Lineage-specific growth inhibition of
NK cell lines by FOXO3 in association with Akt activation status. Exp
Hematol 2012; 40: 1005–15 e6.
29 Zhang X, Karnan S, Tagawa H et al. Comparison of genetic aberrations in
CD10+ diffused large B-cell lymphoma and follicular lymphoma by compar-
ative genomic hybridization and tissue-fluorescence in situ hybridization.
Cancer Sci 2004; 95: 809–14.
30 Tagawa H, Suguro M, Tsuzuki S et al. Comparison of genome profiles for
identification of distinct subgroups of diffuse large B-cell lymphoma. Blood
2005; 106: 1770–7.
31 Tagawa H, Karube K, Guo Y et al. Trisomy 3 is a specific genomic aberra-
tion of t(14;18) negative follicular lymphoma. Leukemia 2007; 21: 2549–51.
32 Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. Synergistic action of
the microRNA-17 polycistron and Myc in aggressive cancer development.
Cancer Sci 2007; 98: 1482–90.
33 Liu F, Yoshida N, Suguro M et al. Clonal heterogeneity of mantle cell lym-
phoma revealed by array comparative genomic hybridization. Eur J Haema-
tol 2013; 90: 51–8.
34 Fukuhara N, Nakamura T, Nakagawa M et al. Chromosomal imbalances are
associated with outcome of Helicobacter pylori eradication in t(11;18)(q21;
q21) negative gastric mucosa-associated lymphoid tissue lymphomas. Genes
Chromosom Cancer 2007; 46: 784–90.
35 Thorns C, Bastian B, Pinkel D et al. Chromosomal aberrations in angioim-
munoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified:
a matrix-based CGH approach. Genes Chromosom Cancer 2007; 46:
37–44.
36 Salaverria I, Bea S, Lopez-Guillermo A et al. Genomic profiling reveals dif-
ferent genetic aberrations in systemic ALK-positive and ALK-negative
anaplastic large cell lymphomas. Br J Haematol 2008; 140: 516–26.
37 Iqbal J, Weisenburger DD, Greiner TC et al. Molecular signatures to
improve diagnosis in peripheral T-cell lymphoma and prognostication in
angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 1026–36.
38 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’
for medical statistics. Bone Marrow Transplant 2013; 48: 452–8.
39 Honma K, Tsuzuki S, Nakagawa M et al. TNFAIP3 ⁄ A20 functions as a
novel tumor suppressor gene in several subtypes of non-Hodgkin lym-
phomas. Blood 2009; 114: 2467–75.
40 Kato M, Sanada M, Kato I et al. Frequent inactivation of A20 in B-cell lym-
phomas. Nature 2009; 459: 712–6.
41 Mandelbaum J, Bhagat G, Tang H et al. BLIMP1 is a tumor suppressor gene
frequently disrupted in activated B cell-like diffuse large B cell lymphoma.
Cancer Cell 2010; 18: 568–79.
42 Kucuk C, Iqbal J, Hu X et al. PRDM1 is a tumor suppressor gene in natural
killer cell malignancies. Proc Nat Acad Sci USA 2011; 108: 20119–24.
43 Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE
complex involved in synaptic exocytosis at 2.4 A resolution. Nature 1998;
395: 347–53.
44 Asano N, Suzuki R, Kagami Y et al. Clinicopathologic and prognostic sig-
nificance of cytotoxic molecule expression in nodal peripheral T-cell lym-
phoma, unspecified. Am J Surg Pathol 2005; 29: 1284–93.
45 Arita K, Maeda-Kasugai Y, Ohshima K et al. Generation of mouse models
of lymphoid neoplasm using retroviral gene transduction of in vitro-induced
germinal center B and T cells. Exp Hematol 2013; 41: 731–41 e9.
Cancer Sci | October 2015 | vol. 106 | no. 10 | 1461 © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Yoshida et al.
Supporting Information
Additional supporting information may be found in the online version of this article:
Fig. S1. Genetic alterations of STX11, related to Figure 1.
Fig. S2. Functional analysis for STX11 in cell lines, related to Figure 2.
Fig. S3. Western blot analysis of STX11 in cell lines belonging to various cell lineages, related to Figure 3.
Table S1. The characteristics of each cell line.
Table S2. Platforms of array CGH in each histological subgroup.
Table S3. Genetic lesion of STX11 in T-cell lymphomas.
Table S4. Characteristics of patients and cell lines analyzed in this study.
Table S5. Clinicopathological characteristics of PTCL-NOS cases according to STX11 status.
Table S6. Clinicopathological characteristics of PTTL cases according to STX11 status.
Data S1. Supplementary methods.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | October 2015 | vol. 106 | no. 10 | 1462
Original Article
Tumor suppressor STX11 in PTCL www.wileyonlinelibrary.com/journal/cas
